Eli Lilly
-
Potential losses exceed $300 billion! Nearly 200 drugs are facing a patent cliff
For more reports, please follow DrugTimes
-
Shocking! Nearly $1 billion in sales, the blockbuster autoimmune drug Baricitinib’s compound patent and crystal form patent have both been declared invalid in China
DrugTimes will continue to follow up and report in a timely manner
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
Eli Lilly Pipeline Analysis: Gene Therapy Products Accounts for 1/3, What Diseases Are Targeted?
DrugTimes will present more reports on CGT. Please stay tuned
-
Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
-
Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease
Congratulations to Eli Lilly and AD patients!
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals
Warmest congratulations to Eli Lilly and Radionetics Oncology!
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
